Efficacy of peg interferon α-2a in combination with ribavirin in treatment of with hepatitis C cirrhosis patients
10.3760/cma.j.issn.1003-9279.2011.06.023
- VernacularTitle:聚乙二醇干扰素α-2a联合利巴韦林治疗代偿期丙肝后肝硬化疗效观察
- Author:
Guang-Wei LIU
1
;
Chun-Fang WANG
;
Wen-Xia ZHAO
;
Su-Ping MA
Author Information
1. 河南中医学院附属第一医院
- Keywords:
Interferon-alpha;
Liver cirrhosis;
Ribavirin
- From:
Chinese Journal of Experimental and Clinical Virology
2011;25(6):477-479
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical efficacy of PEG Interferon α-2a combined with ribavirin in treatment of with hepatitis C cirrhosis patients.Methods 21 patients with chronic hepatitis C cirrhosis (treated group),were treated with peg-IFNα-2a 135 - 180 μg subcutaneously,i week,ribavirin tablets 800 -1000 mg/d,48 weeks of treatment and follow-up 24 weeks,20 patients with Chronic hepatitis C (control group),were treated with peg-IFNα-2a 135 - 180 μg subcutaneously,1 week,ribavirin tablets 600 - 1000 mg/d,48 weeks of treatment,follow-up 24 weeks,comparison of rapid virological response ( RVR ) rates,early virologic response (EVR) rate,sustained virologic response (SVR) rate,adverse reactions was observed.Results The differences of RVR,EVR,ETVR in two groups is not significant,but SVR in treatment group was lower ( P ＜ 0.05 ),and has a higher incidence bone marrow suppression and anemia ( P ＜ 0.05 ).Flu-like symptoms,hair loss,gastrointestinal reactions and other adverse reactions was no significant difference between the two groups.Conclusion The use of 135 μg peg-IFNα-2a and individual in low-dose ribavirin hepatitis C patients with cirrhosis is more security,could get a good early response,but sustained virologic response (SVR) rates is lower than hepatitis C patients.Blood,liver and kidney function should be closely observed during treatment process.
